Mechanisms: binding, distribution, and clearance
Plasma protein binding determines how much of a drug in blood exists in the unbound or free fraction, and that free fraction is what crosses membranes, reaches target tissues, and is available for elimination. Leslie Z. Benet University of California San Francisco framed this as the free drug hypothesis: only unbound drug is pharmacologically active and cleared. When a drug is highly bound to major plasma proteins such as albumin or alpha-1-acid glycoprotein, the volume of distribution is often reduced because the protein-bound fraction remains largely within the vascular compartment, slowing tissue uptake. Conversely, weak binding increases tissue distribution and apparent volume of distribution.
Clearance depends on whether elimination mechanisms act on bound or unbound drug. For many metabolic and renal processes, only the unbound drug is subject to filtration or enzymatic transformation. Malcolm Rowland University of Manchester and Thomas N. Tozer University of Florida described how for low-extraction drugs, intrinsic clearance and protein binding strongly influence hepatic clearance: increasing the free fraction typically increases clearance because more drug is available to metabolizing enzymes. For high-extraction drugs, hepatic blood flow becomes the dominant determinant, so changes in binding have less effect on clearance.
Clinical, cultural, and environmental implications
Alterations in protein levels change binding and therefore dose response. Hypoalbuminemia from liver disease, acute infection, or protein-calorie malnutrition—conditions more prevalent in some low-resource regions—raises the free fraction of albumin-bound drugs, increasing effects and toxicity risk. Pregnancy and aging also alter binding proteins and require dose adjustments or monitoring. The U.S. Food and Drug Administration discusses these pharmacokinetic principles in regulatory guidance, emphasizing the need to evaluate clinically meaningful changes in unbound concentrations during drug development.
Drug–drug displacement interactions can be clinically important when a new agent displaces an older, highly bound drug, temporarily increasing its free concentration and effect. Therapeutic drug monitoring that measures free drug rather than total concentration is more informative for narrow therapeutic index drugs or when binding is likely altered. Environmental exposures and genetic variants that affect protein expression further introduce population-level variability, underlining the importance of context-aware dosing and monitoring. Understanding plasma protein binding is therefore essential not only for mechanistic pharmacology, but for safe, equitable clinical care across diverse populations.